



THE GROUP

Bracco is an **international Group** active in the healthcare sector and a leader in **diagnostic imaging**. It has 3,700 employees and annual total consolidated revenues of around 1,7 billion euros, 88% of which from international sales. In the [Research and Development](#) area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 2,000 patents.

PRODUCT PORTFOLIO

The **Group's** main products are [contrast agents](#), medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Contrast agents are routinely and widely used in all diagnostic imaging modalities, such as radiographic procedures, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and nuclear medicine.

GLOBAL COMMERCIAL PRESENCE

Bracco contrast media are sold in over 100 countries, both directly and indirectly through branches, joint ventures and licence and distribution agreements. Thanks to the quality and reliability of its products, the **Group** boasts leading positions in the most important geographical areas such as North America, China, Europe and Japan.

RESEARCH AND INNOVATION IN DNA

Research and Development activities are concentrated in the laboratories in [Geneva](#) and Lausanne (Switzerland), Monroe and Silicon Valley (United States) and Italy ([Colleretto Giacosa](#)). Each research center has specialised experience and expertise at the absolute cutting edge in different imaging modalities and operates in synergy with the medical and regulatory departments, whose operations are located in Milan (Italy), Konstanz (Germany), Paris (France), Monroe and Long Island (United States), Montreal (Canada), Mexico City (Mexico), São Paulo (Brazil), Beijing (China), and Tokyo (Japan).

THE PRODUCTION ACTIVITIES

Thanks to constant investment in operating processes, Bracco has reached levels of excellence in quality, in full compliance with all applicable regulations in every country where it operates, and with special attention paid to ecologically sustainable production. The **production activities** of Bracco Imaging are carried out in Italy (Ceriano, Torviscosa, and Colleretto Giacosa), Canada (Montreal), Switzerland (Geneva), Germany (Singen), Japan (Saitama), and China (Shanghai).

NEW ACQUISITIONS:

SURGVISION AND BLUE EARTH DIAGNOSTICS

In October 2017 Bracco acquired [SurgVision](#), a high-tech innovative start-up company specialized in developing a real-time Fluorescence Image Guided Surgery platform combining a targeted imaging agent and a device for efficient tumor visualization during oncology surgical procedures.

In 2019 Bracco Imaging also enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of [Blue Earth Diagnostics](#). The company is active in molecular imaging with innovative agents for positron emission tomography (PET) in patients with suspected recurrent prostate cancer.



OTHER IMPORTANT AREAS OF ACTIVITY

The Bracco diagnostic imaging product portfolio is completed by **medical devices** and **advanced imaging agents injection systems** ([ACIST](#) and Bracco Injengineering). Another important area of activity of the **Bracco Group** regards the healthcare services provided by the [Centro Diagnostico Italiano](#), a polyclinic based in Milan.

THE COMMITMENT TO SUSTAINABILITY

Since its foundation, Bracco has been a **socially responsible company** in each area of activity - in business as in every other context. The company is strongly committed to social, educational, [environmental](#) and [cultural improvement](#) and in the promotion of Gender Equality.